Sandro Francavilla

Sandro Francavilla

Auto-generated profile, based on publicly available information

Sandro Francavilla

Andrology Unit, Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2017 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
GCGiovanni Corona
Giovanni Corona
APAlessandro Pizzocaro
Alessandro Pizzocaro
FLFabio Lanfranco
Fabio Lanfranco
AGAndrea Garolla
Andrea Garolla
FPFiore Pelliccione
Fiore Pelliccione
O(On behalf of the Klinefelter ItaliaN Group (KING)
On behalf of the Klinefelter ItaliaN Group (KING)
Specific factors underlying successful surgical sperm retrieval rates (SRR) or pregnancy rates (PR) after testicular sperm extraction (TESE) in adult patients with Klinefelter syndrome (KS) have not been completely clarified. The aim of this review was to meta-analyse the currently available data from subjects with KS regarding SRRs as the primary outcome. In addition, when available, PRs and live birth rates (LBRs) after the ICSI technique were also investigated as secondary outcomes. An extensive Medline, Embase and Cochrane search was performed. All trials reporting SRR for conventional-TESE (cTESE) or micro-TESE (mTESE) and its specific determinants without any arbitrary restriction were included. Out of 139 studies, 37 trials were included in the study, enrolling a total of 1248 patients with a mean age of 30.9 ± 5.6 years. The majority of the studies (n = 18) applied mTESE, 13 applied cTESE and in one case testicular sperm aspiration (TESA) was used. Additionally, four studies used a mixed approach and in one study, the method applied for sperm retrieval was not specified. Overall, a SRR per TESE cycle of 44[39;48]% was detected. Similar results were observed when mTESE was compared to cTESE (SRR 43[35;50]% vs 45[38;52]% for cTESE vs micro-TESE, respectively; Q = 0.20, P = 0.65). Meta-regression analysis showed that none of the parameters tested, including age, testis volume and FSH, LH and testosterone (T) levels at enrollment, affected the final SRR. Similarly, no difference was observed when a bilateral procedure was compared to a unilateral approach. No sufficient data were available to evaluate the effect of previous T treatment on SRR. Information on fertility outcome after ICSI was available for 29 studies. Overall a total of 218 biochemical pregnancies after 410 ICSI cycles were observed (PR = 43[36;50]%). Similar results were observed when LBR was analyzed (LBR = 43[34;53]%). Similar to what was observed for SRR, no influence of KS age, mean testis volume, LH, FSH or total T levels on either PR and LBR was observed. No sufficient data were available to test the effect of the women's age or other female fertility problems on PR and LBR. Finally, no difference in PR or LBR was observed when the use of fresh sperm was compared to the utilization of cryopreserved sperm. The present data suggest that performing TESE/micro-TESE in subjects with KS results in SRRs of close to 50%, and then PRs and LBRs of close to 50%, with the results being independent of any clinical or biochemical parameters tested.

1 June 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
Donatella PaoliDonatella Paoli
Donatella Paoli
MGMariagrazia Gallo
Mariagrazia Gallo
FRFlavio Rizzo
Flavio Rizzo
Elisabetta BaldiElisabetta Baldi
Elisabetta Baldi
SFSandro Francavilla
Sandro Francavilla
LGLoredana Gandini
Loredana Gandini

11 November 2014 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
AIAndrea M. Isidori
Andrea M. Isidori
GBG. Balercia
G. Balercia
ACA. E. Calogero
A. E. Calogero
GCG. Corona
G. Corona
AFA. Ferlin
A. Ferlin
MMMario Maggi
Mario Maggi
Objective: We developed clinical practice guidelines to assess the individual risk–benefit profile of androgen replacement therapy in adult male hypogonadism (HG), defined by the presence of specific signs and symptoms and serum testosterone (T) below 12 nmol/L. Participants: The task force consisted of eight clinicians experienced in treating HG, selected by the Italian Society of Endocrinology (SIE). The authors received no corporate funding or remuneration. Consensus process: Consensus was guided by a systematic review of controlled trials conducted on men with a mean T < 12 nmol/L and by interactive discussions. The guidelines were reviewed and sequentially approved by the SIE Guidelines Commission and Executive Committee. Conclusions: We recommend T supplementation (TS) for adult men with severely reduced T levels (T < 8 nmol/L) to improve body composition and sexual function. We suggest that TS be offered to subjects with T < 12 nmol/L to improve glycaemic control, lipid profile, sexual function, bone mineral density, muscle mass and depressive symptoms, once major contraindications have been ruled out. We suggest that lifestyle changes and other available interventions (e.g. for erectile dysfunction) be suggested prior to TS. We suggest that TS should be combined with currently available treatments for individuals at high risk for complications, such as those with osteoporosis and/or metabolic disorders. We recommend against using TS to improve cardiac outcome and limited mobility. We recommend against using TS in men with prostate cancer, unstable cardiovascular conditions or elevated haematocrit. The task force places a high value on the timely treatment of younger and middle-aged subjects to prevent the long-term consequences of hypoandrogenism.

1 February 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
FPFiore Pelliccione
Fiore Pelliccione
AMAlessandro Micillo
Alessandro Micillo
GCGiuliana Cordeschi
Giuliana Cordeschi
ADAnatolia D’aNgeli
Anatolia D’aNgeli
SNStefano Necozione
Stefano Necozione
SFSandro Francavilla
Sandro Francavilla

1 June 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
ABArcangelo Barbonetti
Arcangelo Barbonetti
BCBenedetta Cinque
Benedetta Cinque
MVMaria Rosaria Caterina Vassallo
Maria Rosaria Caterina Vassallo
SMSalvatore Mineo
Salvatore Mineo
SFSandro Francavilla
Sandro Francavilla
FFFelice Francavilla
Felice Francavilla

28 April 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CCChiara Castellini
Chiara Castellini
SDSettimio D’andrea
Settimio D’andrea
GCGiuliana Cordeschi
Giuliana Cordeschi
MTMaria Totaro
Maria Totaro
APAntonio Parisi
Antonio Parisi
ABArcangelo Barbonetti
Arcangelo Barbonetti
The dogma of mitochondria as the major source of energy in supporting sperm motility should be critically reconsidered in the light of several experimental data pointing to a major role of glycolysis in mammalian spermatozoa. In this light, the reported positive correlation between the mitochondrial membrane potential (ΔΨm) and motility of ejaculated spermatozoa cannot be explained convincingly by an impaired mitochondrial ATP generation only. Evidence has been produced suggesting that, in human sperm, dysfunctional mitochondria represent the main site of generation of reactive oxygen species (ROS). Furthermore, in these organelles, a complex bidirectional relationship could exist between ROS generation and apoptosis-like events that synergize with oxidative stress in impairing sperm biological integrity and functions. Despite the activity of enzymatic and non-enzymatic antioxidant factors, human spermatozoa are particularly vulnerable to oxidative stress, which plays a major role in male factor infertility. The purpose of this article is to provide an overview of metabolic, oxidative and apoptosis-like inter-linkages of mitochondrial dysfunction and their reflections on human sperm biology.